Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma Review
| Authors: | Silk, T.; Silk, M.; Wu, J. |
| Review Title: | Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma |
| Abstract: | Barcelona clinic liver cancer (BCLC) intermediate stage hepatocellular carcinoma is a heterogenous disease. Transarterial chemoembolization is offered as the first line therapy in this disease stage. Recent advances in systemic therapy have markedly improved outcomes even in advanced stage disease. The use of systemic therapy in BCLC intermediate stage disease may now be of therapeutic benefit in selected patients. We will focus on “the up to seven” criteria and its utility in selecting systemic therapy. ©The Author(s) 2022. |
| Keywords: | treatment response; overall survival; review; hepatocellular carcinoma; sorafenib; bevacizumab; chemoembolization; liver cell carcinoma; patient selection; systemic therapy; cancer patient; cancer staging; ticilimumab; cancer immunotherapy; progression free survival; tumor volume; practice guideline; immunotherapy; medical oncology; drug combinations; brivanib; nivolumab; regorafenib; lenvatinib; human; pembrolizumab; durvalumab; orantinib |
| Journal Title: | World Journal of Gastroenterology |
| Volume: | 28 |
| Issue: | 23 |
| ISSN: | 1007-9327 |
| Publisher: | Baishideng Publishing Group Inc |
| Date Published: | 2022-06-21 |
| Start Page: | 2561 |
| End Page: | 2568 |
| Language: | English |
| DOI: | 10.3748/wjg.v28.i23.2561 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- Export Date: 1 August 2022 -- Source: Scopus |
